Marshall Wace LLP Acquires 30,703 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Marshall Wace LLP grew its stake in Immunocore Holdings plc (NASDAQ:IMCR) by 14.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 248,654 shares of the company’s stock after purchasing an additional 30,703 shares during the period. Marshall Wace LLP’s holdings in Immunocore were worth $8,427,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Primecap Management Co. CA boosted its stake in Immunocore by 3,841.6% in the 2nd quarter. Primecap Management Co. CA now owns 1,951,070 shares of the company’s stock valued at $66,122,000 after buying an additional 1,901,570 shares in the last quarter. Bellevue Group AG grew its holdings in shares of Immunocore by 4,817.1% in the 4th quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock worth $66,684,000 after purchasing an additional 956,204 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Immunocore by 10.2% during the 4th quarter. Wellington Management Group LLP now owns 4,312,611 shares of the company’s stock worth $294,638,000 after purchasing an additional 399,201 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Immunocore by 86.3% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 342,000 shares of the company’s stock valued at $22,230,000 after purchasing an additional 158,455 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in Immunocore by 1,867.3% in the second quarter. SG Americas Securities LLC now owns 160,358 shares of the company’s stock valued at $5,435,000 after buying an additional 152,207 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on IMCR shares. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Immunocore in a report on Tuesday, September 17th. Barclays dropped their price target on Immunocore from $92.00 to $66.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Oppenheimer reissued an “outperform” rating and issued a $89.00 price objective (up previously from $87.00) on shares of Immunocore in a research note on Friday, August 9th. Needham & Company LLC lowered their target price on Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a research note on Tuesday, September 17th. Finally, JPMorgan Chase & Co. cut their price target on Immunocore from $70.00 to $66.00 and set an “overweight” rating for the company in a report on Wednesday, July 10th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and a consensus price target of $80.40.

Immunocore Price Performance

Shares of IMCR stock opened at $31.40 on Monday. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -25.74 and a beta of 0.73. Immunocore Holdings plc has a 12 month low of $29.76 and a 12 month high of $76.98. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. The stock has a 50-day moving average price of $35.94 and a 200 day moving average price of $45.16.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.25. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The company had revenue of $75.40 million during the quarter, compared to analysts’ expectations of $74.58 million. During the same quarter in the previous year, the company earned ($0.37) EPS. Immunocore’s revenue was up 26.2% on a year-over-year basis. Research analysts expect that Immunocore Holdings plc will post -1.79 EPS for the current year.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.